# Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

> **NCT00995488** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Urothelial Cancer
- Bladder Cancer

## Interventions

- **DRUG:** ABI-007 (Abraxane®)

## Key facts

- **NCT ID:** NCT00995488
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Terminated prematurely due to low accrual.
- **Last updated:** 2015-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00995488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00995488, "Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00995488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*